Natco Pharma demerger plan approved by board: What it means for agro and core business
Natco Pharma plans to demerge its agro business from its core pharmaceutical business, with the Board’s approval. This move is expected to unlock value, drive long-term growth, and provide operational flexibility and separate branding for each entity. Natco may retain a minority stake in the new company and Board has authorized management to evaluate the demerger and suggest a capital structure.